Literature DB >> 15254027

Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.

Borann Sar1, Didier Monchy, Mich Vann, Chantary Keo, Jean Louis Sarthou, Yves Buisson.   

Abstract

OBJECTIVES: Cryptococcal meningitis is the third-most-common opportunistic infection in HIV patients in Cambodia. Hospitalized patients were given amphotericin B for initial therapy followed by fluconazole for maintenance therapy. The antifungal drug susceptibility of Cryptococcus neoformans isolated from cerebrospinal fluid (CSF) was determined.
METHODS: Isolates of C. neoformans were collected during active laboratory-based surveillance, the first batch from April 2000 to March 2001 (134 new cases), the second batch from April 2001 to March 2002 (268 new cases). Etest strips were used to determine the MICs of amphotericin B and fluconazole. The antigenic agglutination slide test was used for serotyping.
RESULTS: The MIC(50)s and MIC(90)s of fluconazole changed significantly from year 2000 to 2002; the MIC(50)s increased from 4 to 12 mg/L, and the MIC(90)s from 12 to 96 mg/L. For amphotericin B, the MIC(50)s and MIC(90)s remained stable. Moreover, in the second batch, fluconazole MICs were >/=256 mg/L for 20 isolates. By serotyping, it was found that 98.5% of the isolates were serotype A.
CONCLUSIONS: C. neoformans strains isolated from CSF of AIDS patients in Cambodia remain susceptible in vitro to amphotericin B. These strains are less susceptible in vitro to fluconazole, 2.5% being resistant in the first year and 14% in the second year of study. Nevertheless, in vitro resistance of C. neoformans to fluconazole appeared to be linked to extended maintenance treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254027     DOI: 10.1093/jac/dkh361

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Francisco de Assis Baroni; Walderez Gambale
Journal:  Mycopathologia       Date:  2011-11-10       Impact factor: 2.574

2.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

3.  Combined therapies in a murine model of blastoschizomycosis.

Authors:  Carolina Serena; M Mar Rodríguez; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

4.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.

Authors:  Nelesh P Govender; Jaymati Patel; Marelize van Wyk; Tom M Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  Use of a suspension array for rapid identification of the varieties and genotypes of the Cryptococcus neoformans species complex.

Authors:  Mara R Diaz; Jack W Fell
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

6.  Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya.

Authors:  Rennatus Mdodo; Stephen A Moser; Walter Jaoko; John Baddley; Peter Pappas; Mirjam-Colette Kempf; Inmaculada Aban; Susan Odera; Pauline Jolly
Journal:  Mycoses       Date:  2011-05-03       Impact factor: 4.377

7.  In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

Authors:  Carolina Serena; Belkys Fernández-Torres; F Javier Pastor; Luciana Trilles; Márcia Dos Santos Lazéra; Nicole Nolard; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 8.  Efflux-mediated antifungal drug resistance.

Authors:  Richard D Cannon; Erwin Lamping; Ann R Holmes; Kyoko Niimi; Philippe V Baret; Mikhail V Keniya; Koichi Tanabe; Masakazu Niimi; Andre Goffeau; Brian C Monk
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

9.  Human immunodefeciency virus associated cryptococcal meningitis at a tertiary care centre: diagnostic tools and antifungal susceptibility testing.

Authors:  Rashmi Munivenkataswamy; Anjana Gopi; Shaik Mohammed Usman
Journal:  J Clin Diagn Res       Date:  2013-08-01

10.  Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival.

Authors:  Oscar Zaragoza; Cara J Chrisman; Maria Victoria Castelli; Susana Frases; Manuel Cuenca-Estrella; Juan Luis Rodríguez-Tudela; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-06-28       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.